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ABSTRACT
Background. There has been a rise in opioid-related hospitalizations, emergency
department visits, and mortality due to opioid poisoning across Canada. There is a gap in
research related to Nurse practitioner (NP) opioid prescribing and safety measure
utilization patterns and sparse literature related to physician opioid prescribing (Pittman
et al., 2020).
Purpose. A mixed methods approach, specifically an explanatory sequential three-phase
study, was undertaken to explore this topic. The initial phase was development of the
quantitative survey, followed by collection and analysis of the quantitative data. A final
qualitative phase added insight into the quantitative results. There were four objectives
for this study to 1) identify opioid medications prescribed by NPs in Ontario for acute
conditions, chronic non-cancer pain conditions, cancer pain, and palliative symptom, 2)
examine NPs safety measure utilization when prescribing opioids in Ontario, 3) explore
which provider factors (years in practice, practice location, and setting) are associated
with NP utilization of The 2017 Canadian Guideline for Opioids for Chronic NonCancer Pain and 4) survey NP confidence levels when prescribing opioids.
Results. Quantitative results from an online survey completed by NPs in Ontario (n =
158) indicated that the top three opioid medications prescribed for both acute and chronic
pain were hydromorphone followed by acetaminophen with codeine and oxycocet. The
top three acute conditions treated by NPs with opioids were 1) fracture, 2) postoperative/surgical pain, and 3) joint or muscle strain/sprain. The top three chronic
conditions were 1) cancer/palliative care pain, 2) chronic low back pain, and 3)
osteoarthritis. NPs in inpatient settings reported utilizing safety measures less often than
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their community counterparts. Qualitative follow-up was conducted via one-on-one semistructured interviews with NPs (n = 14) from various geographic locations in Ontario.
Results from these interviews revealed that hydromorphone was the preferred opioid due
to its appealing side effect profile and the ability to prescribe smaller doses, especially in
the elderly. Nurse practitioners practicing in inpatient setting did not use safety measures
as often as the community NPs given that institutional policies and safeguards are in
place related to opioid prescribing and dispensing. However, regardless of setting, most
NPs (n = 11) felt that limiting medication supply or controlled dispensing was the most
effective safety measure when prescribing opioids. The impact of the COVID-19
pandemic was explored as a potential contributing factor to the results but was not
influential. NPs expressed feeling more confident prescribing opioids when the patient
has an established diagnosis and are less confident with patients who have a history of
addiction to alcohol or other substances, when the patient diagnoses are not clear, and
with chronic pain patients taking high dosages of opioids.
Conclusion. Nurse practitioners in Ontario are highly under-researched. Findings from
this study can inform curricula changes to incorporate education related to opioid
prescribing in the populations in which NPs expressed less confidence and education
related to opioid tapering for patients on high doses of opioids. Recommendations from
this study include the development of specific opioid prescribing guidelines for NPs
practicing in inpatient settings. This study did not collect data from NPs working
specifically in emergency departments, which would be a topic for future research.
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CHAPTER 1
Nurse practitioners (NP) in Ontario play a vital role in providing care for patients
across the lifespan. The role and education of NPs in Canada have evolved over the past
48 years. Educational programs for NPs in Ontario were suspended from 1983 to 1995
due to the increased number of medical school seats added in the late 1970s (NPAO,
n.d.). In 1993, the former Minister of Health, Ruth Grier, called for health care reform. In
1995, the NP university program was re-established, followed by the Expanded Nursing
Service for Patients Act in 1998. This act authorized NPs to perform three additional
controlled acts: communicating a diagnosis, ordering a limited number of medications
from a defined drug list, and ordering specific laboratory tests, x-rays, and ultrasounds
(NPAO, n.d.). NPs were not permitted to initiate patient referrals to specialists and were
required to consult with a physician partner if they encountered this situation. Initially,
the role of NPs was established to improve the public’s accessibility to basic primary
health care services. Since then, the NP scope of practice has expanded to include many
services provided by other primary health care providers, such as family physicians.
Nurse Practitioners and Opioid Prescribing
In Ontario, NPs are registered nurses (RN) with clinical experience who complete
additional graduate-level education in programs approved by the College of Nurses of
Ontario (CNO). Upon completion of the licensure exam, successful candidates can
register with the CNO with a NP-Primary Health Care, NP-Adult, or NP-Pediatrics
certification, depending on their background education.
In Canada, the NP scope of practice is regulated by provincial regulatory bodies
and varies between provinces. Nurse practitioners work in various health care settings
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ranging from acute care inpatient hospitals to primary health care practices and provide
care for patients across the lifespan.
The Canadian federal government regulates the prescribing and dispensing of
controlled substances via the Controlled Drugs and Substances Act (Government of
Canada, n.d.). This act has eight schedules of substances, including medications,
regulated by the federal government in the interest of public safety. This act was
amended to include NPs and granted them the authority to prescribe controlled
substances in 2012. The first provinces and territories in Canada to adopt this legislation
and permit NPs to prescribe controlled substances were the Yukon, Manitoba, and
Quebec in November of 2012. From 2012 to 2017, the remaining Canadian provincial
regulatory bodies authorized NPs to prescribe controlled substances, with Ontario being
the last province to adopt this policy in April 2017 (O’Rourke et al., 2019). Opioid
prescribing was included in the authorization to prescribe controlled substances.
Practicing NPs who graduated before 2017 and want to obtain authorization to prescribe
controlled substances, including opioids, must submit proof to the CNO of successfully
completion of one of the three CNO-approved programs for controlled substances
education. The approved courses are available at the University of Ottawa, Athabasca
University, or the University of Toronto. Nurse practitioners who choose not to complete
the required education to prescribe controlled substances have this notation on their
license. The researcher for this study is an NP entitled to practice with the CNO, holds a
Primary Health Care certification, has successfully completed controlled substances
education, and worked in an urban emergency department (ED) and urgent care centre for
10 years and is a faculty member at a university in Southwestern Ontario.
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Primary Health Care Nurse Practitioner (PHCNP) programs instituted curriculum
changes to reflect the increase in prescriptive authority in 2017. As of 2017, all students
entering a PHCNP Program in Ontario have controlled substances education embedded in
their program of study and could prescribe controlled substances upon successful
completion of the licensure exam. The CNO also updated the NP Practice Standard to
include standards related to prescribing controlled substances (CNO, 2019). In Canada,
midwives, podiatrists, NPs, physicians, dentists, and veterinarians are permitted to
prescribe opioids, included in schedule I (Government of Canada, n.d.).
In contrast to Canada, the United States has five drug schedules that define a
drug’s potential for misuse or drug-related harm. Schedule I is the class with no accepted
medical usage and a high potential for misuse (such as heroin), whereas schedule V
includes drugs with lower potential for misuse and dependence (such as tramadol)
(United States Drug Enforcement Administration [DEA], n.d.). Prescribers in the United
States must hold a current federal Drug Enforcement Administration (DEA) licence.
People in health fields who are authorized to hold a DEA licence and prescribe from
schedules II to V include physicians, physician assistants, NPs, optometrists, dentists, and
veterinarians (DEA, n.d.). In the United States, NPs have been surveyed at a national
level every five years since 1989 regarding all prescribing practices. Currently, Canada
lacks regular NP practice surveys and a national drug monitoring program.
Opioids
Opioids are a classification of drugs naturally derived from the opium plant. They
can be either “strong” or “weak” based on their potency (Canadian Institute for Health
Information [CIHI], 2019). They are natural and semi-synthetically manufactured and
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distributed in various formulations. Examples of opioids include oxycodone,
hydromorphone, morphine, and codeine. These formulations vary in strength and are
described using morphine milligram equivalents to provide a basis for comparison. For
example, according to the 2017 Canadian Guideline for Opioids for Chronic Non-Cancer
Pain, morphine 30 milligrams is equivalent to hydromorphone 6 milligrams (Michael G.
DeGroote National Pain Centre, 2017). Opioids are available in both immediate and
controlled-release preparations. The word opioid is often used interchangeably with the
term analgesic, but it is important to understand they describe different, albeit sometimes
overlapping, groups of medications. Analgesics refer to all medication classes that relieve
pain. Opioids are primarily used to treat pain, specifically moderate to severe pain. They
also can induce euphoria or a “high” feeling which can be a precursor for prolonged use
or misuse (Canadian Centre on Substance Use and Addiction, 2020). These medications
have the potential for many adverse events, often referred to as opioid harms.
Opioid Indications
Pain can be divided into two broad categories: acute pain and chronic pain. Acute
pain is usually self-limiting, whereas chronic pain continues beyond three months
duration and is not related to malignancy (Public Health Agency of Canada, 2018).
Furthermore, chronic pain is subdivided into chronic cancer and chronic non-cancer pain
(CNCP). A challenge for primary health care providers in Canada is the prevalence of
CNCP, which includes diagnoses such as osteoarthritis, musculoskeletal pain,
fibromyalgia, and neuropathic pain. In Canada, pain is one of the most common reasons
for seeking care, with 1 in 5 adults experiencing chronic pain (Schopflocher et al., 2011).
Opioids have a role in treating chronic pain but are not first-line therapy, and in
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randomized control trials they demonstrated no benefit versus placebo beyond three
months duration (Meske et al., 2018). The risks of opioid prescribing must be weighed
against the benefits in this population, especially for those at elevated risk of addiction or
misuse. It should be noted that there are other indications for opioid initiation, such as the
treatment of cough and opioid dependence (CIHI, 2019).
Scope of the Problem
Canada, per capita, is the second-largest consumer of opioids in the world (CIHI,
2017). In 2016, 21.5 million prescriptions for opioids were dispensed, increasing from
20.2 million in 2012 (CIHI, 2017). Parallel with the rise in opioid prescriptions there has
been an increase in hospitalizations due to opioid poisoning, sometimes referred to as
overdose, resulting in 17 hospital admissions per day in 2017 (CIHI, 2018). Ontario had a
73% increase in ED visits from 2016 to 2017, the highest in Canada, for opioid poisoning
(CIHI, 2018). Between January 2016 and June 2018 there were 9,000 opioid-related
deaths in Canada (Public Health Agency of Canada, 2018). Canadian statistics indicate
that 1 out of every 550 people who are prescribed a long-term opioid die within 2.5 years
of the initial opioid prescription (CIHI, 2019)
This dissertation focused on the role NPs have in prescribing opioids. One area of
concern is that although NPs can prescribe opioids, the CNO NP Practice Standard does
not include resources or tools to guide NP prescribing, such as ‘The 2017 Canadian
Guideline for Opioids for Chronic Non-Cancer Pain’ (Michael G. DeGroote National
Pain Centre, 2017) which are the national guidelines for prescribing opioids. In contrast,
the United States DEA supports a national prescription monitoring program which alerts
prescribers if patients consult multiple providers for opioid prescriptions. In addition,
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national NP practice and prescribing of all medications has been analyzed via a national
survey distributed at 5-year intervals that commenced in 1989 (Goolsby, 2005). Canada
could benefit from adapting similar monitoring practices for NPs in Canada. This mixed
methods study aimed to explore NP opioid prescribing and safety measure utilization
patterns in Ontario as a first step in addressing this gap in knowledge.
The NP curriculum in Ontario was revised to include opioid prescribing and
tapering education beginning in 2017. However, due to the legalities associated with
opioid prescribing and lack of observed structured clinical exams in the associated
student therapeutics course, NP students cannot participate in hands-on experience in
these activities. Also, given that NP controlled substances education pre and post 2017 is
not standardized, we must assess if practicing NPs feel confident in their ability to safely
prescribe opioids when managing acute and chronic pain. Data gathered from this
dissertation provided insight into the outcome of interest, specifically NP opioid safe
prescribing patterns. Information collected regarding factors that influence NPs
utilization of safety measures when prescribing, the top opioid-treated conditions, and NP
confidence in opioid prescribing for acute and chronic conditions provided additional
insight into NP practice and opioid focused education in Ontario.
Study Objectives
The purpose of this mixed methods sequential explanatory study was to identify
the top three-opioid treated acute and chronic conditions, the most prescribed opioid
associated with these conditions, to explore factors that influenced NP opioid prescribing
and safety measure utilization, and survey NP confidence when prescribing opioids.
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There were four objectives for this study, 1) to identify opioid medications
prescribed by NPs in Ontario for the following health conditions: acute conditions such
as cough, fractures, strains, sprains (lasting less than three months), chronic non-cancer
pain conditions such as low back pain, osteoarthritis, rheumatoid arthritis, irritable bowel
syndrome, fibromyalgia, pelvic pain, migraine (lasting greater than three months), cancer
pain, and palliative symptoms, 2) to examine NPs safety measure utilization when
prescribing opioids in Ontario, 3) to explore which provider factors (practice location and
setting) are associated with NP utilization of The 2017 Canadian Guideline for Opioids
for Chronic Non-Cancer Pain (Michael G. DeGroote National Pain Centre, 2017) in
Ontario, and 4) to survey NP confidence when prescribing opioids.
Philosophical Foundation and Conceptual Framework
Philosophical inquiry is vital for understanding nursing education, practice, and
knowledge (Rega et al., 2017). The philosophical foundation that guided this dissertation
was pragmatism. This study explored NP opioid prescribing and safety measure
utilization patterns in Ontario, to address a gap in the existing literature (Pittman et al.,
2020). Pragmatic research is motivated by anticipated outcomes (Nowell, 2015) and was
utilized to conceptualize the practice-theory gap in NP practice and to contribute to
addressing this gap by illuminating actual NP practice. A more expanded review of the
philosophical foundation can be found in chapter three.
The Donabedian Framework served as the conceptual foundation for the study as
it aligned with the study objectives. This framework, established in 1966, used the triad
of structure, process, and outcome to evaluate the quality of health care (Ayanian &
Markel, 2016). Donabedian (1988) clearly stated that structure and process are inherently
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linked to outcomes and should not be looked at as separate entities. This study explored
the structures, processes, and outcomes related to NP opioid prescribing and safety
measure utilization. Structure variables included influential factors such as NP practice
setting/location, patient factors including history and diagnoses treated with opioids,
opioid selection, and clinical setting factors of practice type/location. Process variables
included NP opioid prescribing patterns, the safety measures selected and utilized by NPs
when prescribing opioids, and NP perceptions of safe prescribing. The outcomes of
interest were NPs confidence level when prescribing opioids for acute and chronic
conditions and the frequency of NP safety measure utilization when prescribing opioids.
A further description of the conceptual framework can be found in chapter three.
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CHAPTER 2
LITERATURE REVIEW
Usage of prescription opioids in Canada and the United States has increased over
the past 20 years and of note, these two countries had the highest level of opioid
consumption per capita worldwide in 2015 (Pasricha et al., 2018). The increase may be
attributed, in part, to the misleading information given by Purdue Pharma regarding the
risk of dependency associated with the drug OxyContin (Vogel & Sibbald, 2017). The
World Health Organization reported that worldwide there were half a million deaths
attributed to drug use, with more than 70% related to opioids (World Health
Organization, 2020). A recent scoping review by Pittman et al. (2020) identified that
there is sparse literature related to the safety measures utilized by primary health care
providers when prescribing opioids in Canada. Furthermore, the existing literature only
pertains to physicians (Pittman et al., 2020). With the expansion of NP scope of practice,
NPs provide many of the same services as physicians. Given the lack of information
regarding NP practice, literature regarding physician practice was incorporated to provide
insight into NP prescribing and practice.
A narrative literature review was conducted to explore the published literature
regarding the factors that influence providers when prescribing opioids, the clinical
indications associated with an opioid prescription, and the most frequently prescribed
opioids for these conditions. Database searches included PubMed, Cumulative Index to
Nursing and Allied Health Literature (CINAHL), ProQuest, Scopus, and Ovid
MEDLINE. Key search terms included “safe prescribing”, “opioid prescribing”,
“prescribing guidelines”, “opioid guidelines”, and “opioid indications.” The search terms
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were combined with “nurse practitioner”, “physician”, and “primary health care
provider.” Articles printed in the English language in the last five years were included.
The author also created a weekly alert with ProQuest and Ovid to identify any new
literature based on these search terms. Upon completion of these strategies, a university
librarian was consulted to ensure the search was comprehensive. The literature has been
synthesized into the following topics: opioid prescribing, prescribing tools and safety
measures, and prescribing factors.
Opioid Prescribing
Opioids may be prescribed when treating moderate to severe pain. The selection
of opioid is based on the patient’s clinical presentation and reported pain level. Codeine
was the most prescribed “weak” opioid in Canada in 2018, with the top indications being
mild to moderate pain and cough (CIHI, 2019). Of the available “strong” opioids used to
manage moderate to severe pain, hydromorphone (Dilaudid) was the most prescribed
opioid, followed by oxycodone and morphine (CIHI, 2019). The CIHI report Opioid
Prescribing in Canada: How Are Practices Changing? completed in 2019, noted that the
duration for opioid initiation decreased in the four days or greater categories from 2013 to
2018 but increased in the 1 to 3-day range from 27.8% to 30.1% (CIHI, 2019). This
report also noted that opioid prescription duration increases with the patient’s age, with
seniors being prescribed opioids for an average of 18.6 days (CIHI, 2019).
The 2017 Canadian guidelines recommended a significant decrease in the daily
morphine milligram equivalent dose from 200 milligrams to 90 milligrams, which
complicated the process and required many providers to taper opioids. Pittman et al.
(2020) noted that many Canadian physicians do not receive education regarding safe
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opioid tapering which may lead to inadequate skills when tapering them. Allen et al.
(2013) suggested that physicians lack education regarding opioid prescribing; when
physicians were presented with knowledge questions regarding safe prescribing, only two
of nine questions were answered correctly. This knowledge test was repeated in 2018 and
again, physicians only correctly answered two knowledge questions correctly (Furlan et
al., 2020). Roy et al. (2017) examined overall physician confidence with prescribing
opioids and noted that 42% of physicians felt that their pain management education was
inadequate. The author was unable to find any literature that described Canadian NP
opioid prescribing, tapering, or satisfaction with opioid and pain management education.
To the researcher’s knowledge, there is no literature in Canada that explicitly explores
NP opioid prescribing.
Prescribing Tools and Safety Measures
There are prescribing guidelines available as resources for providers when
prescribing opioids for patients. The Centers for Disease Control (CDC) and Prevention
released new national guidelines for prescribing opioids for chronic pain in the United
States in 2016. With the help of McMaster University, Canada quickly followed and
published ‘The 2017 Canadian Guideline for Opioids for Chronic Non-Cancer Pain’.
These guidelines closely mirrored those established by the CDC and provided prescribers
with ten recommendations for prescribing and tapering opioids for various patient
populations and conditions. As part of the recommendations outlined in the document,
there are several suggestions for prescribers to mitigate the risks associated with opioid
prescribing (Michael G. DeGroote National Pain Centre, 2017). The 2017 guidelines
advise prescribers to utilize safe practices such as limiting number of tablets, urine drug
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screening, not co-prescribing with benzodiazepines, treatment agreements, co-prescribing
with naloxone, screening for risk of opioid addiction, fentanyl patch exchange
(performed by pharmacists), and assessing for underlying mental health issues, before
opioid initiation (Michael G. DeGroote National Pain Centre, 2017). Naloxone is a
medication that temporarily blocks the effects of opioids and is beneficial in the event of
an overdose to allow time for medical attention. The recommended safety measures are
outlined in Table 1.
Table 1
Description of Safety Measures
Safety Measure
Limiting the Number of Tablets
Prescribe No Refills

Screen for Concomitant Benzodiazepine
Use

Complete Opioid Dependence Risk
Assessment

Perform Urine Drug Screen

Description
Limit the number of opioid tablets
prescribed at one time.
Prescribing no refills is the standard of
care in which a provider must reassess
patients to determine if further opioids are
indicated.
Co-prescribing of benzodiazepines with
opioids has a significant association with
patient harms such as increased
respiratory and sedative effects. They
should not be co-prescribed.
Completing an opioid dependence risk
assessment includes screening for patient
factors that may indicate the patient’s risk
for future opioid misuse.
Useful for patients currently taking or
being considered for opioid prescription.
It can be performed frequently for patients
at elevated risk for misuse or in the
presence of aberrant drug-related
behaviours to ensure the patient is, in fact,
taking the medication as prescribed.
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Safety Measure
Complete Treatment Agreement

Screen for Underlying Mental Illness

Co-Prescribe Naloxone (Narcan)

Description
Useful in structuring a process of
informed consent regarding opioid use
and clarifying expectations for both
provider and patient.
Patients with underlying anxiety,
depression, psychiatric diagnosis, mood
disorder, or post-traumatic stress disorder
may be at increased risk for future misuse
or worsening of their underlying mental
illness.
Indicated in patients taking high doses of
opioids, a complex medical history or
comorbidities, having an opioid addiction,
or for patients who recreationally use
opioids. Naloxone prescription also
highlights the potential for serious adverse
events, such as overdose and death,
related to opioid prescription.

An additional interactive tool, the Opioid Manager, developed by the Centre for
Effective Practice in Toronto, Canada, provides an algorithm for the initiation of therapy
in opioid naïve patients, including the previously identified safety measures. The tool is
available in electronic and paper format, can be integrated into electronic medical
records, and has been translated into several languages. It includes a checklist with
multiple history questions and education topics to ensure appropriate and safe opioid
prescribing. The tool was revised in 2017 with the support of the University Health
Network in Toronto, Canada, to reflect the recommendations included in the Canadian
guidelines. There are also other opioid prescribing risk assessment tools (e.g., the Opioid
Risk Tool [ORT], Screener and Opioid Assessment for Patients with Pain [SOAPP], the
[SOAPP-R], and the Current Opioid Misuse Measure [COMM]) that are free and
available online. All have been validated for use except for the SOAPP (Ducharme &
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Moore, 2019). The guidelines, however, do not include a specific recommendation
directing prescribers to utilize these tools. Both in the United States and Canada, these
guidelines serve as recommendations only and are not mandatory to guide opioid
prescribing.
At a global level, the United Kingdom has a National Institute for Care and
Excellence that offers pathways for managing various chronic non-cancer and palliative
conditions (National Institute for Care and Excellence, 2021). These guidelines are
similar to those in the United States and Canada, guiding prescribing based on the
patient’s pain severity. For patients with severe pain or pain with failed non-steroidal
anti-inflammatory treatment, a weak opioid is recommended as treatment (National
Institute for Care and Excellence, 2021). The Australian Government’s Department of
Health has recently introduced new measures to reduce opioid-related harms. They
require pharmaceutical companies to provide smaller pack sizes of immediate-release
opioids, add additional warnings regarding appropriate circumstances for opioids
prescribing, improve the information available to prescribers, and update prescribing
indications to ensure opioid benefits outweigh the risks (Australian Government,
Department of Health, 2021).
Prescribing Factors
Many factors have the potential to influence the prescribing process. Patient
assessments and provision of treatment is an ongoing and iterative process requiring
providers to make decisions based on the patient’s presenting complaints and provision of
an accurate, comprehensive history. Two U.S. studies demonstrated that patient
satisfaction and patient expectations significantly influenced opioid prescribing (Carrico
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et al., 2018; Onishi et al., 2017). Click et al. (2018) explored opioid prescribing in rural
family practices in the United States, the top five factors considered by providers were 1)
their relationship and level of comfort with the patient, 2) patient truthfulness, 3) pain
contracts, 4) access to alternate therapies, and 5) concerns for personal safety.
Alternatively, in a study conducted by Pomerleau et al. (2016) that reviewed factors
affecting decisions regarding opioid prescription in the ED, the top five factors in this
practice setting included 1) patient’s opioid prescription history, 2) patient’s history of
substance abuse or dependence, 3) diagnosis thought to be the cause of the patient’s pain,
4) clinical gestalt, and 5) provider’s concern about unsafe use of the medication. Given
the differences between the factors that affect opioid prescribing in a family practice
versus the ED, it may be inferred that practice setting is an influential element and should
be considered in the opioid prescribing process.
There is sparse literature regarding provider opioid prescribing based on gender.
Varney et al. (2016) examined the differences in opioid prescribing of staff physicians,
residents, physician assistants, and NPs in the ED related to provider gender, patient age,
and years in practice. Varney et al. (2016) found that male providers were more likely to
prescribe opioids than females when they were, and were not, concerned about opioid
misuse, with the greatest difference being amongst providers with five or more years of
experience. Pearson et al. (2017) found no correlation between provider confidence in
managing chronic pain and provider age, sex, race, provider type years in practice,
practice facility/location, or the number of weekly patient encounters. However, Jamison
et al. (2014) found that male gender and increased age were associated with higher levels
of confidence when prescribing opioids for primary care providers. A recent study
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regarding ED opioid prescribing noted that when physicians shared their opioid
prescribing data, overall opioid prescribing rates decreased (Boyle et al., 2019).
A Canadian study by O’Rourke et al. (2019) examined factors that influenced NP
prescribing of all controlled substances, (e.g., stimulants and sedatives in addition to
opioids) in Alberta, Manitoba, and Saskatchewan. The data demonstrated that five
variables were associated with an increased frequency of prescribing 1) location of
practice, 2) area of practice, 3) previous nursing experience, 4) team environments, and
5) common diagnoses (O’Rourke et al., 2019). Of interest was the finding that NPs with
previous or current experience in high acuity environments, such as hospital settings or
critical care, were more likely to prescribe controlled substances (O’Rourke et al., 2019).
The authors attributed this to the fact that in these settings patients are likely to be ill
enough to be admitted (O’Rourke et al., 2019). However, the ED is a unique outpatient
area within the hospital where providers may change by the hour. It is a high-stress,
rapid-paced environment where patient conditions range from non-urgent to resuscitative
measures (Canadian Association of Emergency Physicians, 2013). Due to this fact,
nurses, NPs, and physicians have access to medications, including opioids, that are not
accessible on inpatient units. Physicians have reported that in the ED, time presents a
barrier in terms of completing comprehensive patient histories before prescribing
medications (Moore et al., 2017). Canada lacks ED-specific guidelines for opioid
prescribing, research into this specific area could provide valuable information to guide
prescribers, including NPs, in this rapidly changing, high-stress environment.
Currently, there is limited literature related to the indications for opioid
prescribing and factors that may influence the process. The existing literature relates only
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to physicians as primary health care providers and served as a basis for comparison for
NP practice given the large overlap in roles. This study aimed to illuminate the practice
of NPs who prescribe opioids in Ontario, the factors that influence both opioid
prescribing and safety measure utilization, and NP confidence in managing acute and
chronic pain conditions.
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CHAPTER 3
METHODS
To answer the study objectives, an explanatory sequential mixed methods
approach was used. This methodology is advantageous as it utilizes quantitative and
qualitative methods in a sequential approach that achieves methodological triangulation
(Morse, 1991). The research objectives for this dissertation centered around the
prescribing practices and safety measures utilized by NPs in Ontario. These activities are
complex phenomena that were best analyzed through the integration of quantitative and
qualitative study designs. This mixed methods approach collected and analyzed
quantitative and qualitative data within a single study (Creswell & Creswell, 2018). The
motivation for combining these methods is that neither method on its own would
sufficiently capture the complex topic of NP opioid prescribing. When merged, these
methods can provide a more in-depth description of the research problem. Through
mixed methods strategies, a researcher can present integrated knowledge about the topic
of interest (Plano Clark & Creswell, 2015). Within this study design, the researcher can
corroborate the quantitative and qualitative findings, thereby increasing the validity of the
results (Doyle et al., 2009).
Philosophical Foundation
Philosophical inquiry in nursing is helpful for knowledge development and
facilitating the linkage between theory, research, and practice (Reed, 2018). Pragmatism
was the underlying philosophical worldview that guided this study. Pragmatism is
defined as an approach that assesses the meaning of theories or beliefs in terms of the
success of their practical application (Oxford Languages, n.d.). This philosophical
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worldview is supported by the original work of Peirce (1839-1914), who was considered
the father of pragmatism. His philosophy was concerned with logical action in order to
understand phenomena (Burch, 2001). Dewey (1922) further added to this work and
stated that the only way we can acquire knowledge is through a combination of action
and reflection. This philosophical approach aims to provide solutions to everyday
problems. Hartrick Doane and Varcoe (2005) noted that pragmatism and pragmatic
inquiry draw attention to the inseparability of theory and practice. The four commonly
identified worldviews are post-positivism, constructivism, transformative, and
pragmatism. Post-positivism is tied to quantitative methods, constructivism is rooted in
qualitative methods, thereby leaving transformative and pragmatism as single paradigms
suitable for mixed methods (Hall, 2013). A single paradigmatic approach provides a more
reliable roadmap for mixed methods research as shifting worldviews within one study is
not realistic (Creswell & Tashakkori, 2007). Pragmatism as a basis for mixed methods is
reinforced in the literature with an aim toward solving practical problems in the “real
world” (Feilzer, 2010). Mixed methods research incorporates both quantitative and
qualitative research designs, which may be viewed as competing philosophical
paradigms. Johnson and Onwuegbuzie (2004) argue that pragmatism offers researchers a
middle ground. This philosophy aligned with the research objectives as the goal is to
employ action-oriented research to establish usable outcomes for NP practice.
Pragmatism is a paradigm that encourages researchers to utilize both quantitative
and qualitative research approaches, instead of viewing them as incompatible methods, to
gain a comprehensive understanding of a research problem (Creswell & Creswell, 2018).
Through a pragmatic lens, these two methodologies, performed sequentially or
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concurrently, can be viewed as feeding into one research interest (Creswell & Creswell,
2018). Furthermore, as noted by Biesta (2015), explanatory research aims to identify
causes, factors, or correlations that can influence future events, which aligns with the
objectives of this study. Quantitative findings alone would not capture the experiences of
NPs when prescribing opioids for patients. When combined with qualitative research, this
phenomenon can be more fully captured. Knowledge gained from this dissertation will
inform NPs who are expert clinicians and have an appreciation for results that are
practical and practice oriented.
Conceptual Framework
The Donabedian Framework served as the conceptual framework that guided this
study. The Donabedian Framework examines the relationship between structure, process,
and outcomes to assess the quality of health care interventions. Examining structure and
process elements can assist in achieving ongoing development and improvements in NP
education and practice and optimize patient clinical outcomes (Gardner et al., 2013).
This framework has been utilized by the Registered Nurses Association of
Ontario (2012) to create patient quality care indicators, to assess structures that support
quality care, and to evaluate knowledge and its use. It has also been used by The Royal
College of Physician and Surgeons of Canada (2012) to establish guidelines for
physicians when implementing quality improvement strategies in their practice. This
framework, when applied to health care, ensures quality is safeguarded and professional
autonomy and self-regulation are preserved (Best & Neuhauser, 2004). Furthermore,
Bryant-Lukosius et al. (2016) identified the Donabedian Framework as a robust
framework that can be used to understand and evaluate the advanced practice nursing role
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from the perspective of provider, patients, and policy-makers. This study applied the
Donabedian Framework to explore the process of NP opioid prescribing and safety
measure utilization patterns, and specific variables that provide the structure for this
practice and influence the outcomes.
Donabedian (1988) outlines structure as representing the characteristics of the
setting and/or the people being studied and the tools and resources available in the
physical and organizational setting in which they practice. The process refers to clinical
activities such as diagnosis, treatment, and patient education designed to meet outcomes
(Donabedian, 2003). Outcomes can include changes in patient health that affect their
quality of health (Donabedian, 2003) and reflects the effectiveness of the structure and
process (Donabedian, 1988). It should be noted that the relationship between structure,
process, and outcomes is often imperfect and not always linear (Donabedian, 2003).
Figure 1 illustrates the variables of interest in this study. Structure variables
included NP practice setting/location, patient factors (i.e., history and diagnoses related to
opioid treatment/ selection), and clinical setting factors (i.e., practice type/location).
Process variables were NP opioid prescribing patterns and the safety measures selected
and utilized by NPs when prescribing opioids. The outcomes of interest were NPs’
confidence level when prescribing opioids for acute and chronic conditions, the
frequency of NP safety measure utilization when prescribing opioids, and NP perceptions
of safe prescribing. Acknowledging the interconnection between these elements will
provide valuable insight into the factors that influence NP opioid prescribing and safety
measure utilization and NP prescribing confidence. Findings on the structures, processes,
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and outcomes can inform educators and policy decision-makers on what is currently
working and opportunities for improvement.
Figure 1
Donabedian Framework

Explanatory Sequential Design
In this study design, phase one included the development and testing of a survey
exploring NP prescribing patterns, safety measures, and resources utilized when
prescribing opioids. The second phase was quantitative and involved participant
recruitment, survey distribution, quantitative data collection, and analysis. The third
phase was qualitative, in which the researcher collected qualitative data from interviews
that explained the quantitative findings (Creswell & Creswell, 2018). This data-driven
approach drew insight into the patient and setting characteristics, whereas the content
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analysis involved in the qualitative phase highlighted the key contextual factors
influencing opioid prescribing patterns.
Phase I: Survey Development
This study involved the development of a survey that examined the top three NP
acute and chronic opioid-treated conditions, and the three most often prescribed opioids
associated with these conditions in Ontario. The survey also explored resources and
safety measures utilized by NPs when prescribing opioids and NP confidence when
prescribing opioids. The survey addressed a current gap in the literature regarding NP
practice, including prescribing activities, in Ontario. A recent scoping review by Pittman
et al. (2020) highlighted the current lack of peer-reviewed research regarding NP safety
measure utilization since available research concerning primary health care provider
opioid prescribing in Canada is limited to physicians.
The survey development phase began with review and adaptation of questions
from the Nurse Practitioner Practice Standard and Controlled Substances Authority: Post
Implementations Survey, obtained from the CNO (Tilley et al., 2019) (Appendix A) and
the 2004 American Association of Nurse Practitioners National Nurse Practitioner Survey
(Goolsby, 2005). These surveys focused on different areas. The Canadian survey
examined all controlled substances in Canada; the American survey collected data on all
prescribed medications and was not available for review by the researcher. These surveys
were not validated for use as noted by the authors (Goolsby, 2005; Tilley et al., 2019).
The CNO permitted the researcher to adapt their survey for use in this dissertation. The
survey was adapted to make it specific to opioid prescribing and included many of the
same questions used in the original survey with additional questions added about the
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safety measures outlined in the 2017 Canadian Guideline for Opioids for chronic noncancer pain. The survey was developed using the Qualtrics platform.
Survey development criteria outlined by Dillman et al. (2014) were followed to
ensure the survey questions included clear and unbiased language, questions were asked
one at a time, and guidelines were followed regarding the ordering of questions. The selfreported online survey was structured into three sections intended for completion by all
participants. Section one included questions related to demographic, practice, and
education Information. Data collected for this section included participant age (optional),
NP years of practice experience and practice setting/location information, and source of
controlled substances education. For location, participants were given the options of rural
(<100,000 people) or urban (>100,000) (Statistics Canada, n.d.). Section two contained
questions about participants’ views about use of opioids in practice including opioid
prescribing confidence and opioid prescribing concerns. This section utilized a 5-point
Likert scale 1 (strongly agree) to 5 (strongly disagree) regarding opioid prescribing
concerns and confidence was measured using a scale of 0-100%. Section three collected
data regarding opioid indications, opioid selection and frequency of safety measure
utilization using a 5-point Likert scale ranging from 1 (always) to 5 (never). The survey
sections were adapted from the CNO survey regarding NP prescribing of all controlled
substances.
Face validity was conducted in several steps. In the first step, the dissertation
committee provided feedback on structure and content to ensure it supported the
objectives of the research. In the next step, the online survey was tested by four members
composed of three NPs and one committee member who were asked to comment on
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clarity of questions and survey flow. Content validity of the survey was conducted by an
expert panel that consisted of five members; two NPs (one community-based and one
hospital-based), two NP educators, and the final member was a physician. They were able
to provide feedback from practice and educational backgrounds. Input from a physician
was considered important as it provided additional insight from a profession that works
collaboratively and in consultation with NPs. Other methods of validity were not
implemented as this survey was exploratory and was not designed to measure a concept
(Sullivan, 2011).
The online survey was developed in Qualtrics®. The selected survey format was a
mixed-mode approach that incorporated both online/internet and mailed formats. The
pre-established inclusion criteria for analysis were NPs who 1) are currently registered to
practice with the CNO and work in Ontario, 2) had completed controlled substances
education, and 3) prescribe opioids at least once per week. Given that this was a novel
study, the researcher selected to include NPs who prescribed at once per week to explore
the experiences of NPs who prescribe opioids on a regular basis. Questions in the survey
related to the inclusion criteria, and if criteria were not met, the participant was taken to
the end of the survey utilizing the skip logic feature. This feature allowed the researcher
to exclude participants who did not meet the previously outlined inclusion criteria. For
example, when a participant selected an answer that would exclude them from analysis
(i.e., not currently registered with the CNO), they were taken to the end of the survey.
Therefore, the researcher only collected data from participants who were currently
registered with the provincial regulatory body (CNO), entitled to practice without
restrictions, completed controlled substances education, and currently prescribed opioids
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in their more than once per week in their practice. A copy of the survey can be found in
Appendix B.
The Qualtrics® survey was also designed using the force completion option
where participants were required to select an answer before they could proceed to the
next question. Participant age was not a force completion question as it was not a variable
included in the planned analysis. Dillman et al. (2014) noted that requiring the participant
to share their age may be a deterrent to survey completion. Participant withdrawal was
indicated by incomplete surveys and were deleted after one week. Thus, data were
complete for all sections.
Survey distribution occurred as emails were received in the dedicated email
account. The consent form was adapted from a template from the university Research
Ethics Board (REB) (Appendix B). The survey contained a final custom question that
allowed participants to select if they wished to provide their contact information for a
follow-up interview in the qualitative phase of the study or future studies.
Phase II: Survey Distribution and Quantitative Phase
Following successful dissertation proposal defense and the university REB
clearance (REB #36756), the research proceeded to phase two of the study (Appendix C).
This phase focused on participant recruitment, distribution of the survey, data collection,
and analysis. Participants included currently registered and actively practicing NPs in the
province of Ontario. To recruit participants, the researcher obtained a mailing list of NPs
from the CNO after paying a $300 fee. The NPs on the mailing list were limited to those
who consented to be contacted for research during their annual renewal of CNO
registration. Postcards were mailed in May 2020 and reminder postcards sent in July
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2020 (Appendix D) to the mailing addresses supplied by the CNO. The mailing addresses
were a combination of home and workplace addresses. Postcards explained the research
study, researcher contact information and provided an email address
(NPsurvey2020@gmail.com) that participants could email to gain access to the survey.
Upon sending an email to the email address, participants were provided the survey link
and advised to indicate if they preferred to complete the survey via a paper copy. As an
additional check, the researcher verified that all participants were currently registered to
practice as NPs and prescribe controlled substances in Ontario through the ‘Find a Nurse’
feature on the CNO website. All respondents utilized the online link for survey
completion.
Prior to online survey commencement, the respondents were provided a link to
read and download the consent form. The consent form included information related to
the study purpose, eligibility, procedures, possible risks and harms, benefits of the study,
incentives, voluntary participation, confidentiality, data storage and destruction, contact
for further information, and the potential publication of the findings (Appendix E).
Recruitment incentives included the option to be entered into a raffle for a $250 VISA
gift card. This incentive was optional to mitigate any personal or religious beliefs that
would prohibit participants from completing the survey.
All returned surveys were de-identified and unique codes were given for surveys
in which participants consented for follow-up. A secured and encrypted master file with
identifiers was retained and accessed only by the researcher for data linkage/follow-up.
The survey requested contact information for participants and informed them of the
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optional $25 coffee card compensation they would receive for their time if they
participated in phase three of the study.
There were 3,755 practicing NPs who registered with the CNO as of October 01,
2019 (CNO, 2019), and 2,094 provided the CNO with consent to be contacted for
research purposes. Using a non-probability convenience sampling approach (Elfil &
Negida, 2017), the survey was mailed to all 2,094 NPs. A disadvantage is that the results
may not be generalizable to the population. However, increasing the sample size
increases the statistical power of this method (Suen et al., 2014). In terms of statistical
power, the G*power software indicated that a medium size effect (f=.15) between the
independent and dependent variables involving a multiple linear regression variable using
three predictors with power set at .80 and alpha set at .05, would require a sample size of
85 study participants (G*Power Software Program version 3.1). The anticipated response
rate was approximately 29% based on a previous CNO survey in 2019 (Tilley et al.,
2019). Participant recruitment fell below anticipated numbers (110 recruited over seven
weeks, with less than 85 meeting inclusion criteria), and a reminder postcard was sent to
participants in July 2020. It should be noted that the survey distributed by Tilley et al.
(2019) was sent directly to email addresses registered with the CNO. As noted by
Dillman et al. (2014), mailed recruitment often has lower response rates than web-based
recruitment strategies. Problems with recruitment were mitigated by the addition of social
media recruitment cleared by the university REB. A Facebook page was created that
included the survey email address and a picture of the postcard. These approaches
resulted in a total of 262 participants, with 158 participants meeting inclusion criteria.

29

Quantitative Analysis
Data was de-identified, reported in an aggregate format, and was stored on an
encrypted, dedicated hard drive. SPSS version 26 software was used, and a statistician
was consulted for the analysis. Prior to data analysis, the data was explored for accuracy
of entries, missing data, and statistical assumptions such as normal distribution and
outlier data points (Field, 2005; Hazard Munro, 2005).
Analyses included descriptive statistics such as frequencies, mean, median,
standard deviation, and bivariate and multivariate analyses. A safety measure composite
score was created by combining the mean scores of the 5-point Likert responses
pertaining to the frequency of safety measure utilization including, 1) limiting number of
tablets, 2) prescribing no refills, 3) completing opioid dependence risk assessment, 4)
performing a urine drug screen, 5) completing treatment agreements, 6) screening for
underlying mental health conditions, 7) screening for concomitant benzodiazepine use,
and 8) co-prescribing Narcan. This practice is recommended when a single survey item is
unlikely to be capable of fully capturing the outcome of interest (Song et al., 2017;
Sullivan & Artino, 2011). Reliability of the combined items score was examined and
found to have good internal consistency with the Cronbach's alpha of the composite
safety score is 0.80; a Cronbach's alpha of 0.70 is considered acceptable (Bannon, 2013).
Furthermore, the removal of any of the items in the composite score decreases the alpha
below 0.08. This indicates that all eight items in the composite safety score contribute to
the measurement of a single item and are a good measurement of the scale (Bannon,
2013).
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Independent-samples t-test analysis was used to compare differences between
rural and urban practice setting variables based on the composite safety score. One-Way
analysis of variance (ANOVA) analysis was used to compare differences between the
independent variables with three or more categories (source of controlled substances
education, NP years of experience, primary clinical practice setting, number of patients
seen per day, and number of opioid prescriptions written per week) with the composite
safety score. Assumptions for One-Way ANOVA included 1) that the dependent variable
is continuous; 2) there is two or more independent variables; 3) there is independence of
observation; 4) no significant outliers; 5) the dependent variable has an approximately
normal distribution in the groups; and 6) there is homogeneity of variance. All
assumptions were met.
Multiple linear regression was conducted to determine if the three statistically
significant independent variables clinical practice setting (most hours worked), 2)
number of patients seen per day, and 3) number of opioid prescriptions written per week)
were related to the safety composite score. Test assumptions for multiple linear
regression included 1) one continuous dependent variable; 2) predictors are continuous
or dichotomous categorical variables with variation in values; 3)the continuous variable
has an approximate normal distribution; 4) there is no undue influence from
outliers; 5) independence of observation; 6) there is linearity between the dependent
variable and the predictor variables; 7) multicollinearity does not exist between the
predictor variables; 8) predictor variables are significantly related to the dependent
variable; 9) there is homogeneity of variance; and 10) residual terms should be
independent. All assumptions were met.
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Phase III: Qualitative Phase
Qualitative research can be described as exploratory research. In this phase, semistructured interviews were conducted to explore the quantitative findings. An interview
guide composed of 12 open-ended questions was developed (Appendix F). The research
questions derived from the quantitative results included 1) why hydromorphone was the
most prescribed opioid in all settings for both acute and chronic conditions, 2) why
inpatient NPs used safety measures less often than community/ambulatory (outpatient)
NPs, 3) what was considered the best safety measure in all settings, and 4) what factors
contributed to increased and decreased confidence when prescribing opioids.
Guidance was sought on the structure and content of the questions by the
dissertation committee. Next, the interview guide was tested by interviewing an NP who
had participated in survey testing in phase one. Questions underwent revisions to ensure
questions were posed individually, to improve clarity, and an additional question was
added to explore whether the COVID-19 impacted NP opioid prescribing or patient
population. The interview guide received clearance from the university REB before
proceeding with the interviews (Appendix G).
The follow-up information for participants, including home addresses, was
collected via Qualtrics survey software. To provide a regional NP perspective in Ontario,
the researcher used purposive sampling to select participants from various regions in the
province (Setia, 2016). All interviews were completed by the researcher using a
naturalistic approach where the researcher was the subjective inquirer and explored NPs
experiences with opioid prescribing to generate plausible theory related to the
quantitative results (Hsieh & Shannon, 2005).
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Interviews were completed via the Microsoft Teams platform, and participants
were given the option to have audio, video, or both recorded. Participants completed a
consent process at the beginning of each interview before proceeding to interview
questions. Throughout the interviews, the researcher kept field notes to document
contextual information. Each interview lasted approximately 15 to 30 minutes. Interviews
were conducted until data saturation was achieved. Saturation was achieved by asking
each participant the same questions and creating a saturation grid where the major topics
were listed, and answers were mapped to align with the topics (Fusch & Ness, 2015).
Saturation was achieved after 12 interviews, but two additional interviews had been
scheduled and were completed (n=14). These interviews yielded not further information
and confirmed that data saturation had occurred and were included in analysis. Microsoft
Teams transcription technology was used to transcribe the interviews verbatim. Two
research assistants reviewed and verified the transcripts to ensure accuracy.
Qualitative Analysis
Directed qualitative content analysis was used for the interpretation of the content.
This method was selected as it is appropriate when the qualitative analysis begins with a
theory or relevant research findings (e.g., from a quantitative survey) for guidance (Hsieh
& Shannon, 2005). This technique requires the data to be condensed, labelled, and
grouped into categories of related labels, ultimately formulating summaries or themes.
Analysis was performed within each of the interviews as well as across interviews. Each
participant was labelled by a number (e.g., participant 1). Steps included 1) reading and
re-reading the interview transcripts and making notes, 2) highlighting repetitious answers
for each question across interview transcripts, 3) connecting similar answers across
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interviews, and 4) developing a table organized by interview question and inserting
responses by interviewee. An advantage of content analysis is that it enables data
categorization, allowing patterns to emerge that may not be obvious from listening to
recordings or reviewing transcripts. A disadvantage of content analysis is the researcher
must be aware of their pre-conceived ideas to avoid creating interview or observer bias
that may influence results (Erlingsson & Brysiewicz, 2017). To mitigate this risk, the
researcher was aware of pre-conceived notions based on the quantitative results. The
interview guide was developed and then objectively assessed by the dissertation
committee to ensure the language and questions did not create potential for bias.
Questions were designed to be generalized and open-ended. The interview guide was also
pilot tested with a practicing NP who provided feedback.
Dependability of the qualitative phase was enhanced by using the standardized
interview guide and having two members of the dissertation committee perform
independent reviews of the transcripts and verify the interpretation of the summary
results (e.g. served as a “critical friend”). Question response summaries provided
contextual information that explained the previous statistical results. Summaries of
participant responses were developed for each of the research questions, and quotes that
most accurately depicted the summaries (exemplar quotes) were selected.
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CHAPTER 4
RESULTS
The contents of this chapter will focus first on the quantitative results of the study
then on the qualitative findings that will further explain these results.
Quantitative Findings
SPSS version 26 was used, and a statistician was consulted for analysis.
Survey Response Rate
The survey was mailed to all NPs who provided the CNO with consent to be
contacted for research (N = 2,094). The response rate to the survey was 12.5% (n = 262).
Of the 262 respondents, 158 (60.2%) met the inclusion criteria and were included in the
analysis. This sample size was sufficient for statistical analysis (G*Power Software
Program version 3.1).
Survey Sample Characteristics
Participants’ ages ranged from 27-68 years (Mean = 44.7). Approximately a third
(n = 62, 39.2%) had greater than ten years of NP experience. Seventy-one percent (n =
112, 70.9 %) completed the Primary Health Care NP certification and two-thirds (n =105,
66.5%) worked in an urban setting. Half (n = 86, 54.4%) practiced in outpatient (e.g.,
community or ambulatory care) settings. Forty-two NPs (26.6%) practiced in hospital
inpatient, including long-term care settings. Information was not collected regarding
gender. Participants were from various geographical locations in Ontario as illustrated in
Figure 2. Sample characteristics are presented in Table 2.
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Table 2
Sample Characteristics (n = 158)
Variable

n (%)

NP Years of Experience
<2 years
2-5 years
6-10 years
> 10 years

18 (11.4)
31 (19.6)
47 (29.7)
62 (39.2)

NP Specialty Certification
Primary Health Care
Adult
Pediatric

112 (70.9)
41 (25.9)
5 (3.2)

Population
Urban (≥ 100,000)
Rural (< 100,000)

105 (66.5)
53 (33.5)

Clinical Practice Setting
Hospital Inpatient
Ambulatory
Community
Other

42 (26.6)
30 (19)
56 (35.4)
30 (19)

Number of Patients in Practice Setting
1 – 250
251 – 500
501 – 1000
>1000
Unsure

39 (24.7)
16 (10.1)
19 (12)
48 (30.4)
36 (22.8)

Number of Patients Seen Daily
0-5
6-10
11-15
16 or more

24 (15.2)
44 (27.8)
59 (37.3)
31 (19.6)

Number of Opioid Prescriptions Written Per Week
1-5
115 (72.8)
6-15
32 (20.3)
16 or more
11 (7)
Source of Controlled Substances Education
University of Ottawa
University of Athabasca
Part of NP Program
Other

94 (59.5)
43 (27.2)
14 (8.9)
7 (4.4)
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Figure 2
Distribution of NP Participants on Map of Ontario

Participants mean confidence level (scale 0-100) was 81.3% (SD = 18.1) with a
range of 0-100 for managing acute pain, 67.2% (range 0-100, SD 22.1) for chronic pain,
and 84.9% (range 10-100, SD = 16.6) in their ability to safely prescribe opioids. The top
three opioid-treated acute conditions were fracture (n = 117), post-operative or surgical
pain (n = 114), and joint muscle strain/sprain (n = 62). The top three opioid-treated
chronic conditions were cancer or palliative care-associated pain (n = 124), chronic low
back pain or sciatica (n = 110), and osteoarthritis (n = 102). The top three opioids
prescribed for both acute and chronic conditions were ranked in the same order:
hydromorphone (n = 100, n = 105), acetaminophen with codeine (n = 99, n = 75), and
oxycocet (n = 60, n = 52), respectively. The composite safety score was normally
distributed with a mean of 3.51 (SD = .80) and a range of 1.38-5.00 (see Table 3).
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Table 3
Composite Safety Scores (n = 158)
Variable

M (SD)

Composite Scores

3.51 (.80)

Minimum/
Maximum
1.38-5.00

Skew (SE)
-.35 (.19)

Kurtosis (SE)
-.36 (.38)

Table 4 presents an independent samples t-test analysis and one-way ANOVA
analysis examining safety scores by independent variables. All analyses included Post
Hoc Bonferroni testing to ensure that a significant relationship existed. When multiple
statistical comparisons are made, there is a higher likelihood that results can appear
significant when in fact they are not (Laerd Statistics, 2020). Analysis revealed that
composite safety scores were not significantly related to practice setting (urban vs. rural),
(p = .20), source of controlled substances education (p = .08), and NP years of
experience (p <.01). Composite safety scores were significantly related to clinical
practice setting where NPs in the community used safety measures more often than the
hospital inpatient, ambulatory, and other group (p <.001). Furthermore, composite safety
scores were also significantly related to the number of patients seen per day where the
mean composite safety score for NPs who saw 11-15 patients per day (M = 3.71, SD =
.69) group was significantly higher than the 0-5 patients per day (M = 3.11, SD = .69)
group, while the other groups did not differ significantly (p <.05) based on post-hoc
Bonferroni tests. Lastly, composite safety scores were significantly related to the number
of opioid prescriptions written per week where the mean score for the 1-5 prescriptions
per week (M = 3.61, SD =. 79) group was significantly higher than the 16 or more
prescriptions per week (M = 2.84, SD = .77) group, while the other group did not differ
significantly (p <.01).
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Table 4
Independent Samples T-Test Analysis and One-Way ANOVA Analysis Examining
Composite Safety Scores by Independent Variables (n = 158)
Variable
Practice Setting
Rural
Urban

n (%)

M (SD)

t/F(df)
1.30 (156)

53 (33.5)
105 (66.5)

p
.20

3.63 (.71)
3.45 (.83)

Source of Controlled Substances Education
University of Ottawa
94 (59.5)
3.69 (.75)
University of Athabasca
43 (27.2)
3.35 (.81)
Part of NP Program
14 (8.9)
3.11 (.82)
Other
7 (4.4)
3.00 (.63)

2.29 (3, 154) .08

NP Years of Experience
<2 years
2-5 years
6-10 years
> 10 years

4.60 (3, 154) .004¹

Clinical Practice Setting
Hospital Inpatient
Ambulatory
Community
Other

18 (11.4)
31 (19.6)
47 (29.7)
62 (39.2)

3.37 (.58)
3.58 (.91)
3.30 (.78)
3.68 (.78)
13.85 (3, 154) .001²

42 (26.6)
30 (19)
56 (35.4)
30 (19)

Number of Patients Seen Per Day
0-5
24 (15.2)
6-10
44 (27.8)
11-15
59 (37.3)
16 or more
31 (19.6)

3.21 (.72)
3.25 (.64)
4.00 (.65)
3.27 (.87)
3.37 (3, 154) .023
3.11 (.70)
3.50 (.83)
3.71 (.69)
3.47 (.91)

Number of Opioid Prescriptions Written Per Week
1-5
115 (72.8)
3.61 (.79)
6-15
32 (20.3)
3.39 (.71)
16 or more
11 (7)
2.84 (.77)

5.50 (2, 155) .0054

¹Bonferroni Post Hoc test indicated that there was not a significant difference between
mean score, so this test was not regarded as a significant finding.
²Bonferroni Post Hoc test indicated that the mean score for the Community group
(M=4.00, SD=.65) was significantly higher than the Hospital Inpatient (M=3.21,
SD=.72), Ambulatory (M=3.25, SD=.64), and Other (M=3.27, SD=.87) groups.
3Bonferroni Post Hoc test indicated that the mean score for the 11-15 (M=3.71, SD=.69)
group was significantly higher than the 0-5 (M=3.11, SD=.69) group.
4Bonferroni Post Hoc test indicated that the mean score for the 1-5 (M=3.61, SD=.79)
group was significantly higher than the 16 or more (M=2.84, SD=.77) group.
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Multiple Linear Regression
Composite safety scores were examined by conducting multiple linear regression
(see Table 5) to assess predictors of safety measure utilization. Statistically significant
variables from the ANOVA analysis were included in the model (clinical practice
setting, number of patients seen per day, and number of opioid prescriptions written per
week). The overall model was statistically significant (p <.001) and explained 25% of the
variance in the dependent variable (R2 =. 25, Adjusted R2 = .21). In terms of independent
variables, the predictor clinical practice setting remained significant. Lower composite
safety scores were evidenced by the hospital inpatient (p <.001), ambulatory (p <.001),
and other (p <.001, groups) when compared to the community group. Composite safety
scores did not vary at a statistically significant level by the independent variables number
of patients seen per day and number of opioid prescriptions written per week at the
multivariate level. Therefore, it can be interpreted that NPs who practice in community
settings are more likely to use safety measures more frequently than their counterparts
who worked in other settings in this study.
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Table 5
Multiple Linear Regression Examining Composite Safety Scores (n = 158)
B (SE)

β

p

Clinical Practice Setting
Community (Reference Group)
Hospital Inpatient
Ambulatory
Other

-.68 (.17)
-.66 (.18)
-.60 (.18)

-.38
-.33
-.30

.001
.001
.001

Number of Patients Seen Per Day
0-5 (Reference Group)
6-10
11-15
16 or more

.25 (.19)
.34 (.19)
.28 (.20)

.14
.21
.14

.19
.08
.16

.03
-.15

.74
.06

Variable

Number of Opioid Prescriptions Written Per Week
1-5 (Reference Group)
6-15
.05 (.16)
16 or more
-.48 (.25)

Note: For model = F(157) = 6.18, p <.001, R²=.25, Adjusted R²=.21, p <.001

Qualitative Findings
Sample
One hundred fifty-three participants agreed to be contacted for the follow-up
study. Data collection took place from November 23rd to December 4th, 2020. Semistructured one-on-one interviews were conducted with NPs (n =14) from various
geographical locations in Ontario. Participants included male (n = 5, 35.7%) and female
(n = 9, 64.3%) NPs. Practice settings of the participants included acute care hospital
inpatient, outpatient community care, and long-term care.
Interviews
The interviews were organized based on the summaries that emerged after the
questions of interest were analyzed (Appendix H). These included 1) the setting and
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patient population influenced NP opioid prescribing, 2) NP inpatient setting mitigated
risk, 3) the most effective safety measure was limiting medication supply, and 4) NPs
were confident with established diagnoses and less confident with substance dependence.
Setting and Patient Population Influences Prescribing
Participants’ responses for prescribing demonstrated that prescribing patterns
were influenced by practice setting. NPs practicing in inpatient settings were more likely
to select hydromorphone to treat acute surgical pain with the following rationale provided
by one participant, “Hydromorphone is very quick-acting, it’s very effective”
(Participant 11). The selection process also appeared to be influenced by their team’s
prescribing norms as evidenced by the following answer “I tend to go with what the team
tends to do…sort of the cultural norm” (Participant 13). An interesting finding was that
hydromorphone is preferred due to its favourable side effect profile, especially in elderly
patients, as it can be prescribed in small doses. A participant stated “Dilaudid in the
elderly population …tends to be well-tolerated” (Participant 7), and another concurred,
“I find that it’s better tolerated than morphine with elderly people” (Participant 2).
Inpatient Setting Mitigates Risk
The finding that inpatient hospital NPs used safety measures less often than
community NPs was explored to uncover the rationale behind this observation. Findings
identified that NPs practicing in the acute care inpatient setting were supported by safety
measures in place in the organization, such as RN-controlled dispensing and medication
reconciliation procedures, that mitigated the risks associated with opioid prescribing. A
participant shared the following “…the approach we use...methodical and low dose, and
careful and then the fact that it’s administered by nurses, and it’s monitored…24/7…it’s
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almost like those other checks and balances don’t apply” (Participant 6). Three
participants (8, 11, and 12) reported that they did not use patient treatment agreements in
the hospital setting because it “was not practical.”
Most Effective Safety Measure is Limiting Supply
Almost eighty percent (n = 11, 78.6 %) of participants identified the most
effective safety measure, across all practice setting, was the safe prescribing practice of
limiting opioid supply. This practice included limiting the number of pills, controlled
dispensing (daily or weekly), and not prescribing repeats. Participants responded, “I
make sure it’s controlled dispensing, even during COVID, I think the best thing is really
the dispensing” (Participant 3) and another stated, “The first thing you do is tighten up
dispensing … even daily dispensing if it’s needed” (Participant 4).
Confident with Established Diagnoses and Less Confident with Substance Dependence
Opioid prescribing confidence was explored due to the quantitative finding that
NPs were more confident with acute versus chronic pain management. Analysis of these
answers revealed that NPs were most confident when the patient had an established
diagnosis, such as cancer, or if the patient required palliative care. Participants’ responses
included the following “Like chronic cancer pain because it’s always been the mainstay
of treatment” (Participant 3) and “I would have no hesitation in prescribing opiates for
palliative care” (Participant 2).
The summary findings regarding decreased NP confidence levels when
prescribing opioids were related to patients with a history of addiction to alcohol or other
substances, patients with unclear diagnoses, or patients taking high dosages of opioids. A
participant disclosed, “The population of people who have a known history of substance
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dependence … those are the ones that I find, you know, give me the most anxiety”
(Participant 7). Another participant indicated they are less confident in prescribing
opioids when “There’s no pre-established diagnosis” (Participant 8). The interview
guide contained a question about the COVID-19 pandemic to determine if it was a
potential contributing factor to the results, but it was not influential.
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CHAPTER 5
DISCUSSION
The purpose of this mixed methods sequential explanatory study was to identify
the top three-opioid treated acute and chronic conditions, the most prescribed opioid
associated with these conditions, and to explore factors that influenced NP opioid
prescribing and safety measure utilization. The sequential design involved three-phases.
This method was selected because the objectives of the study would be best achieved by
merging both quantitative and qualitative where each phase builds on the previous phase
with an overall aim to explain the results (Creswell & Creswell, 2018). The utilization of
qualitative research was an effective method of providing a greater understanding of the
intangible factors in this study, such as the opioid selection process and setting factors
that influence opioid prescribing. This study design can be specifically advantageous
when there are unexpected study results. The benefits of conducting mixed methods
research include triangulation, completeness, offsetting weakness and providing stronger
inferences, answering different research questions, explanation of findings, illustration of
data, hypotheses testing, and instrument development and testing (Doyle et al., 2009).
Results from the interviews demonstrated that the most preferred opioid was
hydromorphone due to its appealing side effect profile and the ability to be prescribed in
smaller doses, especially in the elderly. Nurse practitioners in inpatient settings did not
use safety measures as often as outpatient and community NPs. This finding was
attributed to the fact that, in these settings, institutional policies and safeguards are in
place that support safe prescribing. However, regardless of practice setting, most NPs felt
that limiting supply or controlled dispensing was the most effective safety measure when
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prescribing opioids. Nurse practitioners reported increased confidence in prescribing
opioids when patients had an established diagnosis and were less confident with patients
who had a history of addiction to alcohol or other substances, when patient diagnoses
were not clear, and with chronic pain patients who take high dosages of opioids.
This study demonstrated that the Donabedian Framework of structure, process,
and outcome is a valuable and validated conceptual framework that examined NP opioid
prescribing. Additionally, in this study specific structure elements, such as clinical
practice setting, where shown to influence NP safety measure utilization when
prescribing opioids in Ontario. The connection between structure, process, and outcomes
illuminates the requirements for supporting NPs when prescribing opioids to improve NP
confidence and promote quality health care. Through a pragmatic lens, this study
narrowed a gap in the current literature regarding NP opioid prescribing and safety
measure utilization patterns offering theoretical and practical implications for supporting
NPs in these activities.
To the researcher’s knowledge, this is the first Canadian study to examine NP
opioid prescribing and safety measure utilization practices and the influential factors that
impact these activities, so direct comparison with existing Canadian NP opioid
prescribing and safety measure utilization literature is impossible. Thus, relevant
comparisons are drawn from U.S., European, and Australian literature related to all
primary health care providers.
Comparison with Existing Literature
The following sections compare the results of the current study to existing
literature and are organized to align with the objectives of this study.
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Opioid Most Often Prescribed
Results from this study demonstrated that hydromorphone was the top prescribed
opioid for both acute and chronic conditions. Interviews with participants indicated the
preference for hydromorphone was due to its appealing side effect profile and ability to
initiate small doses in the elderly. A recent study by Iaboni et al. (2019) regarding opioid
prescribing in Ontario long-term care residents noted that hydromorphone prescribing
increased by 232.2% during the study period, and the use of other opioids decreased. The
same study attributed the increase to the enhanced tolerability of hydromorphone in renal
impairment and the ability to initiate smaller doses to decrease risks (Iaboni et al., 2019).
Nurse practitioners in the current study reported using hydromorphone most often for
these same reasons. Owsiany et al. (2019) supported the observation that hydromorphone
is the best tolerated oral opioid in patients with chronic kidney disease. Conversely,
Mazer-Amirshahi et al. (2018) raised concerns regarding health care provider familiarity
with hydromorphone potency for dosing compared to morphine as it may increase the
risk for excess dosages. The same study did not specifically explore this concern but
recommended future research on this topic (Mazer-Amirshahi et al., 2018).
Top Three Opioid-Treated Acute and Chronic Conditions
In this study, the top three acute conditions were fracture, post-operative/surgical
pain, and MSK pain. The top chronic conditions were cancer or palliative care-associated
pain, chronic low back pain/sciatica, and osteoarthritis. The most often prescribed opioids
were the same for both acute and chronic conditions; hydromorphone, acetaminophen
with codeine, and oxycocet. Pasricha et al. (2018) examined the clinical indications for
which opioids were prescribed in Ontario from 2015 to 2016. They reported that opioids
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were most often initiated for the following top five pain-associated conditions 1) dental,
2) post-surgical, 3) musculoskeletal, 4) trauma, and 5) cancer/palliative care (Pasricha et
al., 2018). These findings are similar to the clinical indications for which NPs initiated
opioids in this study, except for dental pain. In contrast, a U.S. study conducted by Yang
et al. (2019) examined opioid prescribing trends in the ED between 2005 to 2015 and
noted that the top conditions for which NPs prescribed opioids were injuries (excluding
fractures) and dental pain. Both studies concluded that further research regarding opioid
prescribing would be beneficial (Pasricha et al., 2018; Yang et al., 2019). Current
Canadian and U.S. prescribing guidelines do not provide direction for providers when
treating dental pain (Centers for Disease Control, 2016; Michael G. DeGroote National
Pain Centre, 2017). Thus, research regarding opioid prescribing for this indication would
be beneficial.
Confidence in Prescribing
In this study, NPs reported a mean confidence level of 67.2% regarding their
ability to manage chronic pain. However, confidence in prescribing opioids for both acute
and chronic conditions ranged from 0-100%. One-on-one interviews illustrated that NPs
specifically feel less confident when prescribing opioids for patients with a history of
substance misuse or dependence and with patients on established high doses of opioids.
Pearson et al. (2017) examined physicians, physician assistants, and NPs attending an
opioid conference regarding their confidence in managing chronic pain, and 60.8% stated
they did not feel confident. This finding is consistent with the Jamison et al. (2014) study,
which reported that 84% of the primary care providers felt that managing patients with
chronic pain was stressful. Ebbert et al. (2018) also found in their study of physicians,
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physician assistants, and NPs that only 47% felt confident in their ability to manage
chronic non-cancer pain. Two additional U.S. studies examined the differences in opioid
prescribing patterns between physicians, physician assistants (PA), and NPs. They both
found that in states that did not have opioid restrictions, NPs and PAs prescribed more
opioids than physicians (Ellenbogen & Segal, 2020; Lozada et al., 2020). These studies
attribute the increase in prescribing rates to pharmaceutical companies targeting and
aggressively marketing opioids to these groups (Ellenbogen & Segal, 2020; Lozada et al.,
2020). Hooten et al. (2019) explored physicians who prescribe opioids for chronic pain,
and results demonstrated that physicians are less likely to prescribe for patients with a
history of substance abuse. However, when providers followed a recommended opioid
therapy protocol and were satisfied with their opioid education, their prescribing
confidence increased (Alford et al., 2016; Pearson et al., 2017). These results support
future research regarding this topic.
Safety Measure Utilization
In this study, NPs who practiced in an inpatient hospital or long-term care settings
did not use safety measures as often as NPs working in community or outpatient settings.
Interviews further explored this finding, and NPs in inpatient settings reported that
organizational structures such as RN medication administration and monitoring of
patients mitigated prescribing risks. McCalmont et al. (2018) examined the effect of
geographical setting (urban vs. rural) on prescriber confidence and adherence to CDC
guidelines found no difference between settings. Currently, no literature exists that
pointedly examines primary health care provider opioid prescribing safety measure
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utilization across practice settings, and future research regarding this subject would help
address the gap.
Limitations
There were limitations in this three-part study. A limitation in participant
recruitment was that the postcards containing the study information were mailed to home
and workplace mailing addresses and given the timeframe and implications from the
COVID-19 pandemic, many NPs were working from home and may not have received
the postcard. Despite multi-modal approaches, only 262 NP participants were recruited.
Of the 262 respondents, only 158 met inclusion criteria which, fortunately, was deemed
satisfactory for statistical analysis. A replication of this study in the future may yield a
higher response rate as NPs transition back to the workplace. This survey relied on selfreporting of data by participants. An inherent limitation is that self-reports are subject to
biases such as honesty, interpretation of questions, and the participant’s ability to assess
themselves accurately (Salters-Pedneault, 2020). This survey examined only overall NP
confidence in managing acute and chronic pain in addition to confidence in safe
prescribing. Research regarding NP confidence in specific practice settings may further
illuminate these results. This study was limited to Ontario and therefore is not
generalizable to Canada. Finally, non-probability convenience sampling of only NPs who
consented to research can result in sampling bias as the group is not randomly selected
and may not reflect the population of interest.
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Implications for Nurse Practitioner Education, Practice, and Policy
Education
The results from this study demonstrated that NPs reported decreased confidence
in managing chronic pain, patients with a known history of addiction to substances or
alcohol, and when patients are on established high doses of opioids. This information is
valuable in informing NP education curricula to ensure NP students are provided
comprehensive resources regarding opioid safety measures and the opportunity to engage
in activities, such as experiential learning, to increase their confidence in these areas.
Education should also include information regarding morphine milligram equivalents to
assist NPs when changing opioid classes for their patients. To ensure that graduate NPs
are prepared for practice, educational requirements for NP programs should be
standardized at a national level.
Practice
For practicing NPs, continuing education courses should be aimed at opioid
prescribing for chronic non-cancer, palliative-associated pain, and opioid tapering. The
current NP opioid curriculum is directed toward evaluating patients for opioid aberrant
behaviours. To reduce stigmatization in this patient population, the curriculum could
benefit from a more holistic approach including education for NP students about safe
opioid prescribing resources, including information regarding screening for concomitant
disorders.
Policy
To establish opioid prescribing standards the development of a policy that
requires mandatory pain assessments for patients when initiating or reassessing opioid
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therapy would standardize patient care. Additionally, provincial NP regulatory bodies
should implement processes for monitoring NP prescribing practices. Canada could
benefit from the establishment of a national body that is responsible for addressing the
opioid epidemic.
Future Research
Future research should include studies that explore NP confidence across various
clinical practice settings to determine if confidence in managing chronic pain is
associated with the setting. This study did not explore NPs satisfaction with opioid
prescribing education and its impact on confidence which would be an excellent future
research topic. Given that findings from this study illustrated that NPs practicing in
inpatient settings utilize safety measures less often than community or outpatient NPs,
research should be directed toward the development of opioid prescribing guidelines for
inpatient settings. The current 2017 Canadian Guideline for opioids pertains only to
CNCP. Guidelines to inform safe prescribing in other patient populations are needed.
This study did not collect data specifically from NPs practicing in ED settings. Future
research with NPs in this setting would be beneficial in establishing ED-specific opioid
prescribing guidelines given the complexity of this practice setting. Lastly, this study
identified hydromorphone as the first-choice opioid related to its appealing side effect
profile, especially in the elderly, and research in this area would be beneficial.
Conclusion
Findings from Pittman et al. (2020) and this three-phase sequential explanatory
mixed methods study highlighted the research gap regarding NP prescribing and practice
patterns. To illuminate NP practice and contribution to health care, provincial and
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national regulatory bodies could follow a similar process already established in the
United States, where NPs are surveyed regularly regarding their practice and prescribing
activities.
Results from this study can inform curricula changes to incorporate standardized
education related to opioid prescribing in the populations in which NPs expressed less
confidence and education related to morphine milligram equivalents for opioid tapering,
changing opioids classes, and for patients on high doses of opioids. Recommendations
from this study encourage the development of specific opioid prescribing guidelines for
NPs practicing in inpatient and emergency department settings. The role of the NP is vital
in providing patients access to care across the lifespan in various clinical settings.
Research that can address the theory-practice gap, especially related to practice and
prescribing patterns when it comes to the management of acute or chronic pain, would be
benefit the profession.
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Appendix B
Qualtrics Nurse Practitioner Survey
Nurse Practitioner Survey 2020
Start of Block: Section 1 - Demographic, Practice and Education Information
Q1 Thank you for taking the time to complete this survey. This survey has been
developed in collaboration with the College of Nurses of Ontario.
This survey is part of a research study conducted by Dr. Jody Ralph and Gina Pittman,
from the Faculty of Nursing at the University of Windsor the results of the study will
contribute to dissertation. To view, and if you wish print, the consent form please click
the following link Online_Consent_Form.docx
Q2 After reading the consent form do you agree to proceed to the survey?

o Yes (1)
o No (2)
Skip To: End of Survey If After reading the consent form do you agree to proceed to the
survey? = No
Q3 Age (in years)
________________________________________________________________
Q4 How many years have you practiced as a Nurse Practitioner?

o <2 years (1)
o 2-5 years (2)
o 6-10 years (3)
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o >10 years (4)
Q5 Which NP specialty certificate(s) do you hold? Select all that apply

▢

Adult (1)

▢

Pediatrics (2)

▢

Primary Health Care (3)

▢

Other (4) ________________________________________________

Q6 What is your practice setting?

o Rural (1)
o Urban >100,000 (2)
Q7 In what clinical practice setting do you work the most hours?

o Urgent Care/Walk-in (1)
o Hospital Inpatient (2)
o Hospital Outpatient Clinic (3)
o Emergency Department (4)
o Long-term Care Facility (5)
o Mental Health Ambulatory or Outpatient Service (6)
o Community Health Centre/Family Health Team (7)
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o Nurse Practitioner Led Clinic (8)
o Private Physician Office (9)
o Other (10) ________________________________________________
Q8 How many patients are in your practice setting (if applicable)?

o 1-250 (1)
o 251-500 (2)
o 501-1000 (3)
o >1000 (4)
o N/A or Unsure (5)
Q9 What age category (in years) do you care for most frequently in your practice
setting?

o 0-15 (1)
o 16-45 (2)
o 46-64 (3)
o >65 (4)
Q10 How many patients, on average, do you assess per day?

o 0-5 (1)
o 6-10 (2)
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o 11-15 (3)
o 16-20 (4)
o 21-25 (5)
o >25 (6)
Q11 How many prescriptions (all medications), on average, do you write per week
(including refill prescriptions)?

o None (1)
o 0-10 (2)
o 11-20 (3)
o 21-30 (4)
o 31-40 (5)
o 41-50 (6)
o >50 (7)
Q12 From which source did you complete your Controlled Substances Education?

o I have not completed Controlled Substances Education (1)
o University of Ottawa (CNO approved post graduate program) (2)
o University of Athabasca (CNO approved post graduate program) (3)
o Part of NP Program (4)
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o Other (5) ________________________________________________
Skip To: End of Survey If From which source did you complete your Controlled
Substances Education? = I have not completed Controlled Substances Education
Q13 Do you prescribe opioids in your practice setting?

o Yes (1)
o No (2)
Skip To: End of Survey If Do you prescribe opioids in your practice setting? = No
End of Block: Section 1 - Demographic, Practice and Education Information
Start of Block: Section 2 -Views about use of opioids in your practice
Q14 For the next two questions you will be asked about your confidence with
opioids. Please use the slider bar to indicate your confidence level from 0 to 100%
Q15 I feel confident (0-100%) in my ability to manage patients with:
0

10 20 30 40 50 60 70 80 90 100

Acute Pain ()
Chronic Pain ()

Q16 I feel confident in my ability to safely prescribe opioids
0

0-100% ()

10 20 30 40 50 60 70 80 90 100

78

Q17 Concerns about diversion with affect my willingness to prescribe opioids

o Strongly agree (1)
o Agree (2)
o Neither agree nor disagree (3)
o Disagree (4)
o Strongly disagree (5)
Q18 Concerns about addiction will affect my willingness to prescribe opioids

o Strongly agree (1)
o Agree (2)
o Neither agree nor disagree (3)
o Disagree (4)
o Strongly disagree (5)
Q19 I am concerned about managing pressure from clients to prescribe them opioids

o Strongly agree (1)
o Agree (2)
o Neither agree nor disagree (3)
o Disagree (4)
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o Strongly disagree (5)
Q20 The authority to prescribe opioids makes me concerned about my personal safety

o Strongly agree (1)
o Agree (2)
o Neither agree nor disagree (3)
o Disagree (4)
o Strongly disagree (5)
Q21 The authority to dispense opioids makes me concerned about my personal safety

o Strongly agree (1)
o Agree (2)
o Neither agree nor disagree (3)
o Disagree (4)
o Strongly disagree (5)
End of Block: Section 2 -Views about use of opioids in your practice
Start of Block: Section 3 - You will be asked about your opioid prescribing practices
Q22 How many opioid prescriptions, on average, do you write per week?

o None (1)
o 1-5 (2)
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o 6-15 (3)
o >15 (4)
Skip To: End of Survey If How many opioid prescriptions, on average, do you write per
week? = None
Q23 Do you prescribe non-opioid therapies prior to opioid initiation?

o Yes (1)
o No (2)
Skip To: Q30 If Do you prescribe non-opioid therapies prior to opioid initiation? = No
Q24 If YES to Q22
How often do you prescribe NSAIDs?

o Always (1)
o Very Often (2)
o Sometimes (3)
o Rarely (4)
o Never (5)
Q25 How often do you prescribe physiotherapy?

o Always (1)
o Very Often (2)
o Sometimes (3)
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o Rarely (4)
o Never (5)
Q26 How often do you prescribe massage therapy?

o Always (1)
o Very Often (2)
o Sometimes (3)
o Rarely (4)
o Never (5)
Q27 How often do you prescribe chiropractic care?

o Always (1)
o Very Often (2)
o Sometimes (3)
o Rarely (4)
o Never (5)
Q28 How often do you prescribe acupuncture?

o Always (1)
o Very Often (2)
o Sometimes (3)
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o Rarely (4)
o Never (5)
Q29 Do you prescribe any other non-opioid therapy that is not listed?

o Please Specify (1) ________________________________________________
Q30 What are the THREE main acute conditions (<3 months) for which you prescribe
opioids in your practice setting?

▢

Cough (1)

▢

Joint/Muscle Strain or Sprain (2)

▢

Lower Back Injury (3)

▢

Fracture (4)

▢

Dental Pain (5)

▢

Post-operative or Surgical Related Pain (6)

▢

Other (7) ________________________________________________

Q31 What are the THREE main chronic conditions (>3months) for which you
prescribe opioids in your practice setting?

▢

Chronic Low Back Pain or Sciatica (1)

▢

Fibromyalgia (2)
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▢

Pelvic Pain (3)

▢

Irritable or Inflammatory Bowel Syndromes (4)

▢

Rheumatoid Arthritis (5)

▢

Osteoarthritis (6)

▢

Cancer or Palliative Care Associated Pain (7)

▢

Other (8) ________________________________________________

Q32 For acute conditions, which opioid(s) do you prescribe? Select all that apply

▢

Acetaminophen (Tylenol) with Codeine (1)

▢

Oxycocet (Percocet) (2)

▢

Morphine (3)

▢

Hydromorphone (Dilaudid) (4)

▢

Fentanyl (5)

▢

Other (6)

Q33 For acute conditions, what opioid (including dose and duration) do you most often
prescribe?

▢

Opioid Selected (1) ________________________________________________
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▢

Initial Dosage (2) ________________________________________________

▢

Duration (#of tablets/days/weeks/months) (3)
________________________________________________

Q34 For chronic conditions, which opioid(s) do you prescribe? Select all that apply

▢

Acetaminophen (Tylenol) with Codeine (1)

▢

Oxycocet (Percocet) (2)

▢

Morphine (3)

▢

Hydromorphone (Dilaudid) (4)

▢

Fentanyl (5)

▢

Other (6)

Q35 For chronic conditions, what opioid (including dose and duration) do you most
often prescribe?

▢

Opioid Selected (1) ________________________________________________

▢

Initial Dosage (2) ________________________________________________

▢

Duration (#of tablets/days/weeks/months) (3)
________________________________________________

Q36 When prescribing opioids how often do you perform any of the following?
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Always (1)

Consult

Very Often

Sometimes

Rarely (4)

Never (5)

(2)

(3)

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

Physician
Partner (1)
Limit number
of tablets (2)
Prescribe no
refills (3)
Complete
opioid
dependence
risk assessment
(4)
Urine Drug
Screen (5)
Complete
treatment
agreement (6)
Screen for
underlying
mental health
conditions (7)
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Screen for

o

o

o

o

o

o

o

o

o

o

concomitant
benzodiazepine
use (8)
Co-prescribe
Narcan (9)

Q37 What percentage (0-100%) of the time is a physician available for consultation in
your practice setting?
0

10 20 30 40 50 60 70 80 90 100

Percentage ()

Q38 How often do you use the following sources of information to increase your
confidence when prescribing opioids?
Always (1)

Continuing

Very Often

Sometimes

Rarely (4)

Never (5)

(2)

(3)

o

o

o

o

o

o

o

o

o

o

Education
Course (1)
Journal
Articles (2)
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o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

Pharmacist (6)

o

o

o

o

o

Journal

o

o

o

o

o

Pharmaceutical
Representative
(3)
Consult a
Colleague (4)
Product
Information or
Monograph (5)

Advertisement
(7)

Q39 Are you willing to be entered into a draw for a $250 Visa gift card for your
participation?

o Yes (1)
o No (2)
Skip To: End of Survey If Are you willing to be entered into a draw for a $250 Visa gift
card for your participation? = No
End of Block: Section 3 - You will be asked about your opioid prescribing practices
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Appendix C

Research Ethics Board Application Clearance

Today's Date: March 12, 2020
Principal Investigator: Ms. Gina Pittman
REB Number: 36756
Research Project Title: REB# 20-030: "Nurse Practitioner Opioid Prescribing and Safety Measure
Utilization Patterns in Ontario: An Explanatory Sequential Mixed-methods Study"
Clearance Date: March 9, 2020
Project End Date: February 01, 2021
__________________________________________________________________________
This is to inform you that the University of Windsor Research Ethics Board (REB), which is organized and
operated according to the Tri-Council Policy Statement and the University of Windsor Guidelines for
Research Involving Human Participants, has granted approval to your research project. This approval is
valid for one year after the clearance date noted above.
An annual Progress Report must be submitted for renewal of the project. The REB may ask for monitoring
information at some time during the project’s approval period. A Final Report must be submitted at the end
of the project to close the file.
During the course of the research, no deviations from, or changes to, the protocol or consent form may be
initiated without prior written approval from the REB. Approval for modifications to an ongoing study can
be requested using a Request to Revise Form.
Investigators must also report promptly to the REB:
a) changes increasing the risk to the participant(s) and/or affecting the conduct of the study;
b) all adverse and unexpected events that occur to participants;
c) new information that may affect the risks to the participants or the conduct of the study.
Forms for submissions, notifications, or changes are available on the REB website: www.uwindsor.ca/reb.
If your data are going to be used for another project, it is necessary to submit a secondary use of data
application to the REB.
Sincerely,
Suzanne McMurphy, Ph.D., MSS, MLSP
Chair, Office of Research Ethics
University of Windsor
2146 Chrysler Hall North
519-253-300 ext. 3948
Email: ethics@uwindsor.ca
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Appendix D
Recruitment Postcard
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Appendix E
Consent Form

CONSENT TO PARTICIPATE IN RESEARCH
Title of Study: Nurse Practitioner Opioid Prescribing and Safety Measure Utilization Patterns in
Ontario: An Explanatory Sequential Mixed-methods Study
You are asked to participate in a research study conducted by Dr. Jody Ralph and Gina Pittman,
from the Faculty of Nursing at the University of Windsor the results of the study will contribute
to dissertation.
If you have any questions or concerns about the research, please feel to contact Dr. Jody Ralph
at (519) 253-3000 extension 2271.
PURPOSE OF THE STUDY
The purpose of the study is to gain insight into Nurse Practitioner opioid prescribing and safety
measures utilized when prescribing opioids in Ontario. Nurse Practitioners are under researched
and this will provide valuable information.
PROCEDURES
If you volunteer to participate in this study, you will be asked to:
Complete on online or paper format survey depending on your preference that will take
approximately 10-15 minutes. You will also be asked to provide consent if you wish to participate
in future studies regarding this topic.
POTENTIAL RISKS AND DISCOMFORTS
None
POTENTIAL BENEFITS TO PARTICIPANTS AND/OR TO SOCIETY
By participating in this study, you may learn new insights about your opioid prescribing and
safety measure utilization when prescribing opioids. This information will also illuminate nurse
practitioner practice information, which is currently lacking, in Ontario.
COMPENSATION FOR PARTICIPATION
If you complete and return the survey, and consent, you will be entered into a raffle for a $250
VISA gift card.
CONFIDENTIALITY
Any information that is obtained in connection with this study and that can be identified with you
will remain confidential and will be disclosed only with your permission.
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To ensure confidentiality, data will be encrypted and stored on a dedicated external hard
drive to increase security. Data will be de-identified for data analysis. Data from
consenting participants will be securely stored, ensuring the protection of the privacy of
these individuals, for secondary analyses.
PARTICIPATION AND WITHDRAWAL
Participants will be able to withdraw until survey submission. The investigator may
withdraw you from this research if circumstances arise which warrant doing so.
FEEDBACK OF THE RESULTS OF THIS STUDY TO THE PARTICIPANTS
Date when results are available: Following the publication of any manuscripts from this study,
results will be mailed to the email addresses provided to complete the survey
SUBSEQUENT USE OF DATA
These data may be used in subsequent studies, in publications and in presentations.
RIGHTS OF RESEARCH PARTICIPANTS
If you have questions regarding your rights as a research participant, contact: Research Ethics
Coordinator, University of Windsor, Windsor, Ontario, N9B 3P4; Telephone: 519-253-3000, ext.
3948; e-mail: ethics@uwindsor.ca
SIGNATURE OF RESEARCH PARTICIPANT/LEGAL REPRESENTATIVE
I understand the information provided for the study Nurse Practitioner Opioid Prescribing and
Safety Measure Utilization Patterns in Ontario: An Explanatory Sequential Mixed-methods Study
as described herein. My questions have been answered to my satisfaction, and I agree to participate
in this study. I have been given a copy of this form.
___________________________________________________
Name of Participant
___________________________________________________
Signature of Participant
Date
SIGNATURE OF INVESTIGATOR
These are the terms under which I will conduct research.
____________________________________________________
Signature of Investigator
Date
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Appendix F
Qualitative Interview Guide
Hello
Thank you so much for your interest in my study and agreeing to participate. My name is
Gina Pittman, and I am a PhD Student in the Faculty of Nursing at the University of
Windsor We’ll start with all of our cameras on. If the internet connection gets poor, then
we may need to switch off some or all of the cameras and use the audio-record only.
I’d like to confirm some of the items in your consent form. The purpose of this study is to
gather information about the prescribing patterns of Nurse Practitioners in Ontario. Your
identity will not be tied in any way to any of your responses given. As we go along,
please feel free to modify or decline to answer any question; you may also add any
questions that you think I should have asked. If you need to take a break at any point in
time, please let me know. This study received ethical clearance from the University of
Windsor REB.
I am now going to record our session
Can you please confirm that you are willing to participate in this study and that you
consent to being video/audio taped?
Thank you. Please remember that you may withdraw from this study at any point during
the interview for any reason. Following the interview, you will be given one week to
withdraw your data, again, for any reason. You will also receive an electronic $25 Tims
card for your time.
Thank you, I’m now going to ask you some general questions.
1. Can you tell me about your NP education (Specifically, your opioid education and
continuing education?
2. Can you tell me about your NP career path?
3. How would you describe your practice setting? (urban, rural, size)
4. Can you tell me about your experiences, positive or negative, of prescribing
opioids?
5. Can you tell me about the types of patient conditions for which you prescribe
opioids?
6. Can you tell me how you select which opioid to prescribe for patients? What
opioid do you prescribe most often?
7. Are there patient condition or diagnoses for which you feel more confident when
prescribing opioids?
8. Are there patient condition or diagnoses for which you feel less confident when
prescribing opioids?
9. Has COVID had any impact on your prescribing patterns? How so
10. Has COVID had any impact on the presenting complaints of the patients you
assess? If Yes, How so?
11. In the survey you were asked about safety measures when prescribing opioids. In
your experience what do you feel are the most effective safety measures?
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(memory job – such as limiting tablets, prescribing no refills, treatment
agreements)
Follow-up: What do you feel are the least effective?
12. Is there anything else that you would like to add or something we should have
asked that we did not?
If you think of anything else, please feel free to email me at NPsurvey2020@gmail.com
We will send your electronic gift card to you by email.
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Appendix G
Research Ethics Board Protocol Change Clearance

October 19, 2020
Our File No:
36756
Project Title:
REB# 20-030: "Nurse Practitioner Opioid Prescribing and Safety Measure
Utilization Patterns in Ontario: An Explanatory Sequential Mixed-methods Study"
Status:
Active
Dear Ms. Pittman,
Thank you for submitting your request to revise for "REB# 20-030: "Nurse Practitioner Opioid Prescribing
and Safety Measure Utilization Patterns in Ontario: An Explanatory Sequential Mixed-methods Study"".
This request has been reviewed and you are now cleared to proceed with the proposed changes to
transitioning interviews to an on-line platform.
If we can be of any further assistance, please do not hesitate to contact our office.
Sincerely,
Suzanne McMurphy, Ph.D., MSS, MLSP
Chair, Office of Research Ethics
University of Windsor
2146 Chrysler Hall North
519-253-300 ext. 3948
Email: ethics@uwindsor.ca
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